Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.

International journal of molecular sciences - 9 Nov 2021

Hyun Soonsil, Shin Dongyun

Abstract excerpt

Drug resistance continues to be a major problem associated with cancer treatment. One of the primary causes of anticancer drug resistance is the frequently mutated RAS gene. In particular, considerable efforts have been made to treat KRAS-induced cancers by directly and indirectly controlling the activity of KRAS. However, the RAS protein is still one of the most prominent targets for drugs in cancer treatment....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Melanoma and MAPK Pathways
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Proteolysis

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Share to Small Molecule Libraries

Source

Open in PubMed Open full text

Identifiers

PMID: 34830024
DOI: 10.3390/ijms222212142
PMCID: PMC8621880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers.PMID 34830024Read ↗

Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers.Semantic proximity Read ↗

Recent advances in targeted degradation in the RAS pathway.Semantic proximity Read ↗

Innovative Therapies for Oncogenic KRAS Mutations: Precision Strategies with PROTACs in Cancer Treatment.Semantic proximity Read ↗

Progress in RAS-targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras.Semantic proximity Read ↗

Small-Molecule RAS Inhibitors as Anticancer Agents: Discovery, Development, and Mechanistic Studies.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.Semantic proximity Read ↗

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

Small molecular inhibitors for KRAS-mutant cancers.Semantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.